KRAS and colorectal carcinoma: To address the effect of EGFR mAbs and oxaliplatin on the growth of CRC cells, nine ATCC-derived cell lines (HCA7, Caco-2, LS180, SW620, DLD-1, HCT116, HT-29, RKO, and VaCo-5) were characterized for their KRAS, NRAS, and BRAF mutation status and tested for sensitivity to single agent cetuximab, panitumumab or oxaliplatin using MTT cell viability assay (Table 1; Suppl.